Azitromitsin at Koronavirus is not more effective than placebo for ambulatory patients

Clinical trial of Californian university to San Francisco and Stanford university (United States of America) once again confirmed an antibiotic inefficiency azitromitsina at an easy and moderate current of Koronavirus. In group accepting a preparation in two weeks symptoms disappeared at 50% of participants — as well as in group of placebo. Besides, for the patients who were receiving azitromitsin, the risk of hospitalization was higher. Credit: malachy120 | 123rf.com Azitromitsin, an antibiotic of a wide range of action from group of macroleads-azolidov, suppresses a metabolism of bacterial cages, slowing down their growth and reproduction...